Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study).

Andrea ChiricozziMatteo MegnaAlessandro GiuntaCarlo Giovanni CarreraPaolo DapavoAnna BalatoPiergiorgio MalagoliStella MazzoccoliAurora ParodiSilvia SabatinoCarlotta BuzzoniChu-Han HuangAlessandra Narcisi

Published in: The Journal of dermatological treatment (2023)

This 24-month observational cohort study confirmed that ixekizumab is effective in the long-term management of patients with moderate-to-severe plaque psoriasis.

Keyphrases

coronary artery disease
high intensity
early onset
drug induced